

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number:

32425

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number:

32425

OR

<input type="checkbox"/> Firm or Individual Name			
Address			
City	State	Zip	
Country			
Telephone	Email		


Assignee Name and Address:

DFB Pharmaceuticals, Inc.
318 McCullough
San Antonio, TX 78215

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date	7 Nov. 2005
Name	Mark Mitchell	Telephone	210-476-8180
Title	General Counsel and Vice President Regulatory Compliance		

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Express Mail Label No.: EV109798072US
Date of Deposit: April 4, 2003

Attorney Docket No. 17811-017 CIP (M-17 CIP)

Rec'd PCT/PTO 09 JAN 2006

COMBINED DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a utility patent is sought on the invention entitled:

METHODS AND COMPOSITIONS FOR TISSUE REGENERATION

the specification of which was filed on December 19, 2002 and assigned Serial No. 10/324,257, bearing Attorney Docket No. 17811-017 CIP (M-17 CIP).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56.

- ☒ I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States application listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application:

Application No. (U.S.S.N.)	Filing Date (dd/mm/yy)	Status (Patented, Pending, Abandoned)
60/408,565	6 September 2002	Pending
09/943,114	30 August 2001	Pending
60/230,286	1 September 2000	Abandoned
60/299,003	18 June 2001	Abandoned

APPLICANTS: Rolland, et al.
USSN 10/324,257

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:



30623

PATENT-TRADEMARK OFFICE

Address all telephone calls to Ivor R. Elrifi at telephone number 617/542-6000.
Address all correspondence to:




30623


PATENT-TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or patent issued thereon.

1-00
Inventor's Signature
Full Name of Inventor: Eric Rolland
Citizenship: FRENCH
395, Chemin de Pain Loup
01220 Divonne les bains
France


Date 26/03/2003

2-00
Inventor's Signature
Full Name of Inventor: Thomas Hunziker
Citizenship: SWISS
Schulthesserstrasse 20,
CH-3653 Oberhofen, Switzerland


Date 28/03/2003

APPLICANTS: Rolland, et al.
USSN 10/324,257

3-00

B. Mis

Inventor's Signature
Full Name of Inventor: Beatrice Mis
Citizenship: FRENCH
Rue de Maupas 16
Lausanne 1004
Switzerland

CHX

24.03.2003
Date

400

Christopher Rinsch

Inventor's Signature
Full Name of Inventor: Christopher Rinsch
Citizenship: US
32 Av. Victor Ruffy
Lausanne 1012
Switzerland

CHX

26.03.2003
Date

TRA 1745715v1

STATEMENT UNDER 37 CFR 3.73(B)Applicant/Patent Owner: Eric RollandApplication No./Patent No. 10/526,853 Filed/Issue Date: March 4, 2005Entitled: METHODS AND COMPOSITIONS FOR TISSUE REGENERATIONDFB Pharmaceuticals, Inc., a Corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership,
university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest.
The extent (by percentage) of its ownership interest is _____ %

in the patent application/patent identified above by virtue of either:

- A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as shown below:

1. From: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch To: Isotis SA
The document was recorded in the United States Patent and Trademark Office at
Reel 014463, Frame 0684, or for which a copy thereof is attached.

2. From: Isotis SA To: Episource SA
The document was recorded in the United States Patent and Trademark Office at
Reel 014969, Frame 0088, or for which a copy thereof is attached.


3. From: Episource SA To: DFB Pharmaceuticals
The document was recorded in the United States Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☐ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (*Le.*, a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the USPTO. See MPEP 302.081

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.



Signature

Mark B. Wilson, Reg. No. 37,259

Printed or Typed Name

Attorney
Title

November 15, 2005

Date

(512) 474-5201

Telephone Number

DFBP:010USC1

File Code

Express Mail Label No.: EV475167504US
Date of Deposit: February 16, 2005

Attorney Docket No.: 17811-999

ASSIGNMENT

EpiSource SA, a corporation organized under the laws of **Switzerland**, having principal offices at 1 Rue de Sébeillon, 1004 Lausanne, **Switzerland** ("the ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to **DFB Pharmaceuticals, Inc.**, a corporation organized under the laws of **Texas**, having principal offices at 3909 Hulen Street, Fort Worth, Texas 76107, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE:

(1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of EpiSource SA at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

EpiSource SA hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by EpiSource SA had this assignment, sale and transfer not been made.

EpiSource SA agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


EpiSource SA further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do the necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

EpiSource SA hereby covenants that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.


EpiSource SA further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

For EpiSource SA:

Date: December 15, 2004



Signature of:
Title: Director
EpiSource SA

IN WITNESS WHEREOF,


Signature of witness:

this 15th day of December 2004
Date of signing

IN WITNESS WHEREOF,


Signature of witness:

this 15th day of DECEMBER, 2004
Date of signing

For DFB Pharmaceuticals, Inc.:

Date:

Brook Sharp
Signature of:
Title: Chief Scientific Officer
DFB Pharmaceuticals, Inc.

IN WITNESS WHEREOF,

Nab Singh
Signature of witness:

this 15th day of December 2004
Date of signing

IN WITNESS WHEREOF,

[Signature]
Signature of witness:

this 15th day of December 2004
Date of signing

SCHEDULE A

1. 17811-014-004 (M-14 AU)
Australian Patent Application No. 60098/00
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
2. 17811-014-008 (M-14 CA)
Canadian Patent Application No. 2,379,949
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
3. 17811-014-019 (M-14 EP)
European Patent Application No. 00946228.4
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
4. 17811-014-032 (M-14 JP)
Japanese Patent Application No. 2001-511156
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
5. 17811-014-061 (M-14 WO)
PCT Patent Application No. PCT/IB00/01076
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
6. 17811-014 (M-14)
United States Patent No. 6,548,058
Entitled: "Keratinocyte Culture and Uses Thereof"
7. 17811-014 CIP (M-14 CIP)
United States Patent No. 6,730,513
Entitled: "Keratinocyte Culture and Uses Thereof"

8. 17811-014 NATL (M-14 NATL)
United States Patent Application No. 10/031,188
Entitled: "Improved Keratinocyte Culture and Uses Thereof"
9. 17811-015 (M-15)
United States Patent No. 5,968,546
Entitled: "Keratinocyte Culture from Precursor Cells"
10. 17811-017 (M-17)
United States Patent No. 6,673,603
Entitled: "Cell Paste Comprising Keratinocytes and Fibroblasts"
11. 17811-017 CIP (M-17 CIP)
United States Patent Application No. 10/324,257
Entitled: "Methods and Compositions for Tissue Regeneration"
12. 17811-017-032 CIP (M-17 CIP JP)
Japanese Patent Application No. 2003-157362
Entitled: "Methods and Compositions for Tissue Regeneration"
13. 17811-017-061 CIP (M-17 CIP WO)
PCT Patent Application No. PCT/US03/27888
Entitled: "Methods and Compositions for Tissue Regeneration"
14. 17811-017-004 (M-17 AU)
Australian Patent Application No. 2001286952
Entitled: "Methods and Compositions for Tissue Regeneration"
15. 17811-017-008 (M-17 CA)
Canadian Patent Application No. 2426107
Entitled: "Methods and Compositions for Tissue Regeneration"

16. 17811-017-019 (M-17 EP)
European Patent Application No. 01966441.6
Entitled: "Methods and Compositions for Tissue Regeneration"
17. 17811-017-061 (M-17 WO)
PCT Patent Application No. PCT/US01/27104
Entitled: "Methods and Compositions for Tissue Regeneration"
18. 17811-028 (M-28)
United States Patent Application No. 10/655,435
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"
19. 17811-028-061 (M-28 WO)
PCT Patent Application No. PCT/IB03/04506
Entitled: "Fibrin Cell Supports and Methods of Use Thereof"